TOP 5 MOST VIEWED ARTICLES

RECENT COMMENTS

Azmina: In my personal experience, Medical Oncology teams would love to be able to offer patients concurrent [...]   »Read more

Storme Guy: I agree that false promises or prediction are done in a non correct way. Always, medical oncologist [...]   »Read more

Alex: You use EUS for staging only the smaller tumours. What about using endoscopic mucosal resection for [...]   »Read more

dinha: Please write your comment here   »Read more

headcoverings for chemotherapy: I recently came across your blog and have been reading along. I thought I would leave my first c [...]   »Read more

 

Article type: Cover Story

Keywords: Lesley Fallowfield, doctor-patient communication, psycho-oncology, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Lesley Fallowfield: getting the message across

Lesley Fallowfield:
getting the message
across

It was while studying the benefits of offering patients a choice between radical and breast conserving therapy that Lesley Fallowfield first demonstrated the importance of doctor patient communication. Her findings haven’t always been welcome, but cancer doctors who are now getting trained in talking to patients, and to each other, should know whom to thank.

» Marc Beishon


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.